American journal of ophthalmology · 2026
Validation of the "FIRST-ROP" Algorithm at a Neonatal Intensive Care Unit Tertiary Center over Three Decades.
СтатьяВалидационное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Malek Davina A, Altamirano Francisco, Chaaya Celine, Negron Catherin, Arias Nancy, Lockward Joaquin Sosa, Fan Kenneth C, Al-Khersan Hasenin, Yannuzzi Nicolas A, Hua Hong-Uyen, Berrocal Audina M, Patel Nimesh A
Аннотация
PURPOSE: To validate the FIRST-ROP algorithm in a medium-risk cohort of infants undergoing screening for retinopathy of prematurity (ROP).
DESIGN: Retrospective diagnostic comparison.
METHODS: Infants who did not meet criteria for microprematurity or nanoprematurity (gestational age ≥ 27 weeks and birth weight ≥ 800 g) were included. Outcomes assessed included rates of ROP diagnosis and treatment-warranted ROP (TW-ROP), as well as postmenstrual age (PMA) at first diagnosis and initiation of treatment. Paired binary detection outcomes between traditional ROP screening strategies and the FIRST-ROP algorithm, which defers screening until 34 weeks PMA, were compared using the McNemar test.
RESULTS: Among 8564 infants screened, 3641 (36%) met inclusion criteria, of whom 604 (17%) developed ROP. Median PMA at first ROP diagnosis was 35.1 weeks (interquartile range [IQR], 34.0-36.6 weeks; range, 31.3-51.4 weeks). Median PMA at stage 3 diagnosis was 35.6 weeks (IQR, 34.0-37.0 weeks; range, 32.3-47.6 weeks). Median PMA at first treatment was 40.0 weeks (IQR, 37.1-41.4 weeks; range, 34.3-44.4 weeks). Fifteen infants (2%) required treatment, of whom 10 (67%) had type 1 ROP. Initiating screening at 34 weeks PMA significantly reduced examinations compared with standard screening (P < .001), corresponding to an estimated 17% fewer visits per patient. No cases of TW-ROP would have been missed under the FIRST-ROP strategy (95% CI, 99.3%-100%).
CONCLUSIONS: Over 3 decades, no infants in this medium-risk cohort required treatment before 34 weeks PMA. These findings validate the FIRST-ROP algorithm and support safe deferral of the initial ROP examination to 34 weeks PMA, reducing screening burden while maintaining sensitivity for TW-ROP.
DESIGN: Retrospective diagnostic comparison.
METHODS: Infants who did not meet criteria for microprematurity or nanoprematurity (gestational age ≥ 27 weeks and birth weight ≥ 800 g) were included. Outcomes assessed included rates of ROP diagnosis and treatment-warranted ROP (TW-ROP), as well as postmenstrual age (PMA) at first diagnosis and initiation of treatment. Paired binary detection outcomes between traditional ROP screening strategies and the FIRST-ROP algorithm, which defers screening until 34 weeks PMA, were compared using the McNemar test.
RESULTS: Among 8564 infants screened, 3641 (36%) met inclusion criteria, of whom 604 (17%) developed ROP. Median PMA at first ROP diagnosis was 35.1 weeks (interquartile range [IQR], 34.0-36.6 weeks; range, 31.3-51.4 weeks). Median PMA at stage 3 diagnosis was 35.6 weeks (IQR, 34.0-37.0 weeks; range, 32.3-47.6 weeks). Median PMA at first treatment was 40.0 weeks (IQR, 37.1-41.4 weeks; range, 34.3-44.4 weeks). Fifteen infants (2%) required treatment, of whom 10 (67%) had type 1 ROP. Initiating screening at 34 weeks PMA significantly reduced examinations compared with standard screening (P < .001), corresponding to an estimated 17% fewer visits per patient. No cases of TW-ROP would have been missed under the FIRST-ROP strategy (95% CI, 99.3%-100%).
CONCLUSIONS: Over 3 decades, no infants in this medium-risk cohort required treatment before 34 weeks PMA. These findings validate the FIRST-ROP algorithm and support safe deferral of the initial ROP examination to 34 weeks PMA, reducing screening burden while maintaining sensitivity for TW-ROP.